RadNet, Inc.

NasdaqGM:RDNT 株式レポート

時価総額：US$4.8b

RadNet 配当と自社株買い

配当金 基準チェック /06

RadNet配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.1%

バイバック利回り

総株主利回り-0.1%
将来の配当利回りn/a
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブ更新 • Jun 24

RDNT: Advanced Imaging And AI Platform Expansion Will Support Future Earnings

RadNet's analyst price target has shifted lower by $5 to $65, with analysts pointing to both the recent target cuts from Barclays and B. Riley and ongoing confidence reflected in its inclusion on Jefferies' Franchise Picks list as key context for the revision.
ナラティブ更新 • Jun 06

RDNT: Advanced Imaging And AI Execution Will Support Future Earnings

Narrative Update: RadNet The updated analyst price target for RadNet has shifted modestly lower to around $90 per share. This reflects analysts’ recalibration of fair value and discount rate assumptions, while also acknowledging continuing support from recent research that highlights the stock’s inclusion in high-conviction lists and its relative strength in advanced volume growth and imaging pricing versus peers.
分析記事 • May 14

Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report

Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...
ナラティブ更新 • May 07

RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings

Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.
ナラティブ更新 • Apr 23

RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility

Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.
ナラティブ更新 • Apr 08

RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility

RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.
ナラティブ更新 • Mar 25

RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside

Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.
ナラティブ更新 • Mar 09

RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside

Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.
ナラティブ更新 • Feb 22

RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside

Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.
ナラティブ更新 • Feb 08

RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside

Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.
ナラティブ更新 • Jan 24

RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside

Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.
ナラティブ更新 • Jan 09

RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance

Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.
ナラティブ更新 • Dec 13

RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance

Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.
ナラティブ更新 • Nov 28

RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance

Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.
分析記事 • Nov 14

Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts

Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...
ナラティブ更新 • Nov 13

RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings

RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.
ナラティブ更新 • Oct 30

RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential

Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.
ナラティブ更新 • Oct 15

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.
ナラティブ更新 • Sep 19

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.
分析記事 • Sep 12

RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
ナラティブ更新 • Sep 04

AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics

Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.
Seeking Alpha • Aug 18

RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)

Summary I am downgrading RDNT stock to hold due to excessive capital requirements, bloated acquisitions, and declining returns on invested capital despite strong top-line growth. The valuation is stretched, with RadNet trading at 78x EBIT and >5x book value, while debt levels and working capital intensity have surged. Operating margins are compressing, free cash flow yields have turned negative, and acquisitions are not delivering sufficient economic returns. I will reconsider a more bullish stance only if RDNT demonstrates margin expansion, improved capital productivity, or stronger free cash flow generation. Read the full article on Seeking Alpha
分析記事 • Jul 31

Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Seeking Alpha • Mar 11

RadNet: On The Sidelines For Now

Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking Alpha
Seeking Alpha • Oct 02

RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects

Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking Alpha
User avatar
新しいナラティブ • Aug 30

Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector

Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.
Seeking Alpha • Aug 24

RadNet: Growth In Operating Earnings Off Very Little Incremental Capital

Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking Alpha
Seeking Alpha • Jun 05

RadNet: Qualified Growth Route, Still Undervalued

Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation

Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking Alpha

決済の安定と成長

配当データの取得

安定した配当: RDNTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: RDNTの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

RadNet 配当利回り対市場
RDNT 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (RDNT)n/a
市場下位25% (US)1.3%
市場トップ25% (US)4.1%
業界平均 (Healthcare)1.9%
アナリスト予想 (RDNT) (最長3年)n/a

注目すべき配当: RDNTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: RDNTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: RDNTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: RDNTが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/27 03:45
終値2026/07/27 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

RadNet, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12

アナリスト機関
Sarah JamesBarclays
Andrew MokBarclays
Yuan ZhiB. Riley Securities, Inc.